Status:
COMPLETED
Clinical Study With Lyrica In Patients Suffering From Epilepsy
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Neuralgia
Epilepsy
Eligibility:
All Genders
18+ years
Brief Summary
Clinical study with Lyrica (pregabalin) in patients suffering from epilepsy. This drug is used as adjunctive therapy with one or more antiepileptics. Lyrica has potential to reduce seizure frequency.
Detailed Description
\- Included all adult patients with partial seizures and without contraindications according to Summary of Product Characteristics (SmPC).
Eligibility Criteria
Inclusion
- Adult patients with partial seizures.
Exclusion
- Contraindications according to Summary of Product Characteristics (SmPC).
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
286 Patients enrolled
Trial Details
Trial ID
NCT00922987
Start Date
September 1 2009
End Date
June 1 2010
Last Update
January 25 2021
Active Locations (61)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Banská Bystrica, Slovakia, 97401
2
Pfizer Investigational Site
Banská Bystrica, Slovakia, 975 17
3
Pfizer Investigational Site
Bardejov, Slovakia, 08501
4
Pfizer Investigational Site
Bojnice, Slovakia, 97201